What is HC Wainwright’s Estimate for CMPS FY2030 Earnings?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Research analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Compass Pathways in a research report issued on Monday, March 2nd. HC Wainwright analyst P. Trucchio anticipates that the company will earn $6.46 per share for the year. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($2.33) per share.

Several other research firms have also recently weighed in on CMPS. Compass Point set a $15.00 price target on Compass Pathways in a report on Thursday, February 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st. Morgan Stanley lifted their target price on Compass Pathways from $11.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. Finally, Canaccord Genuity Group upped their price target on shares of Compass Pathways from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Compass Pathways presently has an average rating of “Moderate Buy” and an average target price of $22.13.

Compass Pathways Trading Down 1.0%

Shares of NASDAQ:CMPS opened at $6.95 on Wednesday. Compass Pathways has a 12-month low of $2.25 and a 12-month high of $8.90. The business has a 50 day moving average of $6.98 and a 200-day moving average of $6.12. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55. The stock has a market cap of $667.34 million, a PE ratio of -2.56 and a beta of 1.90.

Hedge Funds Weigh In On Compass Pathways

Several large investors have recently bought and sold shares of CMPS. Royal Bank of Canada raised its stake in shares of Compass Pathways by 49.8% during the first quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock valued at $256,000 after acquiring an additional 29,733 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Compass Pathways by 42.0% in the first quarter. Acadian Asset Management LLC now owns 240,591 shares of the company’s stock valued at $686,000 after purchasing an additional 71,112 shares during the period. Bridger Management LLC bought a new position in Compass Pathways during the 2nd quarter worth $412,000. XTX Topco Ltd acquired a new position in Compass Pathways during the 2nd quarter worth about $220,000. Finally, Hsbc Holdings PLC acquired a new position in Compass Pathways during the 2nd quarter worth about $3,011,000. 46.19% of the stock is currently owned by institutional investors.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.